Introduction
============

Precise, rapid control of blood pressure (BP) is important in emergency and critical care settings as uncontrolled hypertension is associated with morbidity and mortality in high-risk surgery patients as well as severely hypertensive patients. Clevidipine is an ultrashort-acting, vascular and arterial-selective calcium antagonist currently under development for treating acute hypertension.

Methods
=======

We analyzed data from two double-blinded, placebo-controlled trials (ESCAPE-1 and ESCAPE-2) that evaluated the ability of clevidipine to control BP in high-risk cardiovascular surgery patients. In addition, we evaluated the design of a recently initiated trial that analyzes clevidipine in severe hypertension (VELOCITY trial).

Results
=======

In both ESCAPE-1 and ESCAPE-2, clevidipine demonstrated a statistically significant decrease in mean arterial pressure from baseline (*P*\< 0.0001) compared with placebo at the 5-minute time point. A BP lowering effect was observed within 1--2 minutes with clevidipine, with the median time to achieve target systolic blood pressure (SBP) of 6 and 5.3 minutes, respectively (see Figure [1](#F1){ref-type="fig"}). In the patients with acute severe hypertension, the VELOCITY trial studies the percentage of patients in whom the SBP falls below the lower limit of a patient-specific predetermined target range at the initial dose of 2.0 mg/hour within 3 minutes of initiating the infusion, as well as the percentage of patients who reach the prespecified target SBP range within 30 minutes of the beginning of the study drug.
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Conclusion
==========

In both the ESCAPE-1 and ESCAPE-2 studies, clevidipine demonstrated the ability to precisely achieve target blood pressure reductions in a short period of time, in a high-risk patient population. Further analysis of the rapid decreases noted with clevidipine is being conducted in patients with acute severe hypertension in the VELOCITY trial.
